- Home
- PHAT
as 06-06-2025 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 289.0M | IPO Year: | 2019 |
| Target Price: | $16.25 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $19.71 | Next Earning Date: | 05-01-2025 |
| Revenue: | $81,859,000 | Revenue Growth: | 3055.70% |
| Revenue Growth (this year): | 195.45% | Revenue Growth (next year): | 106.76% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Topper James N | PHAT | Director | May 21 '25 | Buy | $3.86 | 3,780 | $14,609.32 | 59,403 | |
| Topper James N | PHAT | Director | May 13 '25 | Buy | $3.24 | 7,420 | $24,462.49 | 59,403 | |
| Topper James N | PHAT | Director | May 9 '25 | Buy | $3.28 | 48,203 | $152,916.63 | 59,403 | |
| Parikh Asit | PHAT | Director | May 6 '25 | Buy | $2.50 | 10,000 | $24,984.50 | 95,500 | |
| Henderson Molly | PHAT | CFO and CBO | Apr 7 '25 | Sell | $4.55 | 3,678 | $16,739.68 | 89,868 | |
| Parikh Asit | PHAT | Director | Mar 13 '25 | Buy | $4.42 | 10,000 | $44,200.00 | 95,500 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
a day ago
Top Midday Gainers
MT Newswires
a day ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires
a day ago
Sector Update: Health Care
MT Newswires
a day ago
Phathom Pharmaceuticals Shares Surge After FDA Grants 10-Year Exclusivity for Acid-Reducing Drug
Investing.com
a day ago
Phathom Pharmaceuticals shares soar on FDA exclusivity grant
GlobeNewswire
a day ago
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
GlobeNewswire
23 days ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.